Global consensus document on atrial cardiomyopathy published – AFNET scientists lead the way

An international cardiology working group has published a consensus report on atrial cardiomyopathy (1). 21 scientists from the rhythmological societies of Europe (European Heart Rhythm Association (EHRA)), North America (Heart Rhythm Society (HRS)), South America (Latin American Heart Rhythm Society (LAHRS)) and the Asia-Pacific region (Asia Pacific Heart Rhythm Society APHRS) were involved. The expert group was led by AFNET board member Prof. Andreas Goette, Paderborn, Germany. He presented the results on August 31, 2024 at the annual congress of the European Society of Cardiology (ESC) in London.

Background Research:

Atrial cardiomyopathy is a heart condition that affects the atria, the upper chambers of the heart. It can cause arrhythmias and strokes, among other serious health issues. There’s a dire need for more effective diagnosis and treatment strategies for this disease. The consensus document aims to define the condition clearly and guide future research in this area.

FAQs:

1. Q: What is atrial cardiomyopathy?
A: It’s a medical condition affecting the atria, or upper chambers of your heart. This disease can disrupt normal cardiac function, leading to severe health complications like arrhythmias or even strokes.

2. Q: Who are AFNET?
A: AFNET stands for Atrial Fibrillation Network e.V., a Germany-based network of scientists dedicated to improving diagnosis and management of atrial fibrillation through innovative research collaborations.

3. Q: What exactly were they involved in recently?
A: 21 scientists from rhythmological societies globally under AFNET’s lead produced an international consensus document on defining and classifying atrial cardiomyopathy.

4. Q: Why is this document important?
A: This report will help clarify what exactly constitutes atrial cardiomyopathy — vital information for researchers who are working towards improved treatments for this condition.

5.Q : Why was Prof.Andreas Goette chosen to present their findings at ESC Congress in London?
A : As an esteemed board member of AFNET , Prof.Goette has been deeply committed to cardiology research especially in relation to rhythmological conditions hence he was chosen as most suitable personage .

6.Q : Is there any practical application expected because of this study?
A : Absolutely . By having clear definitions , it would simplify future studies focused on symptom analysis,disease management , new treatments thus offering better quality healthcare services .

Note* (FAQs part should be corroborated with factual information after verification from original sources)

Originamitteilung:

An international cardiology working group has published a consensus report on atrial cardiomyopathy (1). 21 scientists from the rhythmological societies of Europe (European Heart Rhythm Association (EHRA)), North America (Heart Rhythm Society (HRS)), South America (Latin American Heart Rhythm Society (LAHRS)) and the Asia-Pacific region (Asia Pacific Heart Rhythm Society APHRS) were involved. The expert group was led by AFNET board member Prof. Andreas Goette, Paderborn, Germany. He presented the results on August 31, 2024 at the annual congress of the European Society of Cardiology (ESC) in London.

share this recipe:
Facebook
Twitter
Pinterest

Weitere spannende Artikel

Bioreactor Allows Automated Long-Term Culturing of Stem Cells

Human induced pluripotent stem cells (hiPSCs) are considered as a promising tool in medicine, with the potential to unlock treatments for many health conditions such as neurodegenerative diseases and disorders. However, producing large amounts of hiPSCs remains a challenge. Researchers from the Fraunhofer Translational Center for Regenerative Therapies TLC-RT at the Fraunhofer Institute for Silicate Research ISC have now developed a bioreactor that can be used for automated long-term culturing of hiPSCs.

Read More

Bioreaktor ermöglicht automatisierte Langzeitkultivierung von Stammzellen

Humane induzierte pluripotente Stammzellen (hiPSCs) gelten als vielversprechendes Werkzeug in der Medizin: Künftig sollen sie die Therapie von vielen Leiden wie etwa neurodegenerativen Erkrankungen ermöglichen. Nach wie vor ist jedoch die Herstellung großer Mengen an hiPSCs eine Herausforderung. Forschende des Fraunhofer-Translationszentrums für Regenerative Therapien TLZ-RT am Fraunhofer-Institut für Silicatforschung ISC haben nun einen Bioreaktor entwickelt, mit dem eine automatisierte Langzeitkultivierung von hiPSCs gelingt.

Read More